SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion, primarily driven by the ongoing, contentious acquisition saga surrounding Warner Bros. Discovery, which continues to generate significant uncertainty. This prolonged situation, compounded by mixed analyst sentiment, has led to sharply divided investor opinions, with many debating the stock's "oversold" status as it navigates a challenging environment ahead of its earnings report.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point as the bank kicks off earnings season, with community discussions intensely focused on recent warnings about rising expenses and the potential impact of a proposed credit card interest rate cap. Investors are also digesting the bank's strategic move to take over the Apple Card program and its deeper foray into blockchain and tokenized funds, all while online chatter includes speculation regarding its market positions in commodities.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is gaining attention following a new pre-production order for GPU-accelerated systems for U.S. Army combat vehicles, which is amplifying community anticipation for a much larger defense contract in the burgeoning Edge AI sector. Investors are bullish on the company's focused strategy after a recent asset sale, coupled with its specialized technology, low stock float, and potential for significant growth in defense and AI infrastructure. Discussions highlight the company's strong positioning for future defense spending and AI compute needs at the tactical level.

KOLANA is a koala-character meme coin that has been designed as the newest meme character token to join the Solana ecosystem. It’s a fun, community-driven token with no inherent value, created purely for those who want to participate in the Solana meme culture and become a part of the KOLANA community. While it doesn't offer utility or financial promises, it thrives on community engagement and decentralised fun.

KOLANA

KOLANA CRYPTO is trending as it captures increasing market interest, with community members highlighting its early signs of strength and ability to hold structure amidst volatility. Enthusiasts are actively discussing its steady momentum and balanced movement, advocating for early participation in this crypto asset.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics (TVTX) is generating intense market conversation and significant volatility due to a recent FDA request for additional data to further characterize FILSPARI's clinical benefit for its potential FSGS indication, despite the company reiterating confidence and reporting robust sales for its existing IgAN approval. This immediate uncertainty has polarized the community, with many speculating on a Complete Response Letter (CRL) while others perceive the sharp sell-off as an overreaction, viewing it as a buying opportunity given the high unmet medical need in FSGS.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

Lulus Fashion Lounge (LVLU) is trending due to activist investor Christian Friedland's disclosed stake and call for significant governance reforms, emphasizing the company's "extremely undervalued" status. The community is actively discussing Friedland's assertion that LVLU trades at a 27x valuation gap compared to peers, despite achieving positive adjusted EBITDA and expanded gross margins. This has ignited speculation among traders about a potential "super squeeze" and multi-day run, driven by the proposed reforms and perceived undervaluation.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix is experiencing significant upward momentum following preliminary Q4 and full-year 2025 results that exceeded guidance, showing strong revenue growth. This positive update, coupled with its small float, is fueling intense discussion among traders actively debating its breakout potential and the possibility of a short squeeze, despite ongoing concerns about future dilution.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is experiencing notable volatility and intense community debate after announcing a CFO transition and reiterating its strategy to prioritize long-term user growth and product investment. While some investors view the significant stock decline as an attractive buying opportunity, others express deep concerns about its valuation and the ongoing discussion surrounding AI's potential to disrupt its core business model. The broader conversation centers on Duolingo's capacity to sustain its competitive moat within the dynamic education technology sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as new iGaming legalizations, notably in Maine, and ongoing discussions in other states like New York and Virginia, signal expansion opportunities. The community is actively debating the impact of its recently launched prediction markets platform, while many anticipate strong engagement and revenue from the upcoming NFL playoffs and Super Bowl. This growth is viewed against persistent frustrations over the stock's current valuation despite underlying business momentum and ongoing efforts to expand its regulated online betting footprint.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amidst a surge in geopolitical interest surrounding Greenland's vast rare earth deposits, driven by renewed U.S. efforts to secure critical mineral supply chains against global rivals. The community is actively discussing upcoming high-level meetings between U.S., Danish, and Greenlandic officials, anticipating potential strategic cooperation or investments that could significantly benefit CRML's Tanbreez project. Many investors are buying dips, expressing strong conviction in a substantial upside and highlighting short squeeze potential, while some view recent volatility as a pump and dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to...

Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving Average - Should You Sell?

Verastem (NASDAQ:VSTM) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell...

Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.read more...

<ul class="summary-bullets"><li>While the discontinued trial yielded early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Verastem CMO said.&nbsp;</li><li>Verastem said it will now focus its resources on the clinical development of VS-7375 in advanced NSCLC and other solid tumors.&nbsp;</li><li>VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.</li></ul> Shares of Verastem Oncology (VSTM) fell 2% after hours on Monday after the company said that it has decided to discontinue its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data.No more patients will be enrolled in the trial being conducted in collaboration with Amgen and those already enrolled can continue treatment as per the investigator's discretion, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251229302295/en/Verastem-Oncology-Provides-Update-on-RAMP-203-Phase-12-Clinical-Trial-for-Advanced-KRAS-G12C-Mutant-Non-Small-Cell-Lung-Cancer">said</a>. The trial was evaluating Avutometinib and Amgen’s Sotorasib in a “doublet combination” and also with Defactinib as a “triplet combination” in patients naïve to or previously treated with a KRAS G12C inhibitor, which is a targeted cancer drug that block the specific KRAS G12C mutation.The company said it is assessing opportunities to share data from the interim analysis in the future. &nbsp;<h2 class="st-heading-2">Fresh Focus</h2>Verastem said it will now focus its resources on the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors while also evaluating Avutometinib plus Defactinib in combination with chemotherapy in first line metastatic pancreatic cancer.“While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates,” chief medical officer John Hayslip said.Hayslip added that VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VSTM jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘low’ levels.A Stocktwits user applauded the decision as “sound.”<stembedurl>https://www.stocktwits.com/Drew613/message/640355285</stembedurl>Another opined that the VS-7375 numbers are “very exciting” and said they could see why the company prioritized it over the discontinued trial.<stembedurl>https://www.stocktwits.com/Sawnchey/message/640352752</stembedurl><a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained 50% this year and more than doubled over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 

Equity

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 


Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of...

Squarepoint Ops LLC Boosts Stake in Verastem, Inc. $VSTM

Squarepoint Ops LLC increased its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 2,995.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The...

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Analysts

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat Ratings reports. One...

Insider Selling: Verastem (NASDAQ:VSTM) CEO Sells 2,000 Shares of Stock

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average...

Verastem (NASDAQ:VSTM) CEO Dan Paterson Sells 2,000 Shares

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 2,000 shares of Verastem stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $10.07...

BVF Inc. IL Raises Stock Position in Verastem, Inc. $VSTM

BVF Inc. IL grew its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 62.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$7.11
Prev Close	$7.79
Open	$7.74
Dividend Yield	0.00%
50-Day Moving Average	$8.77
Beta	1.38
Avg. Volume	1.71M
PE Ratio	-1.67

52-Week High	$11.25
52-Week Low	$4.01
Market Capitalization	$586.74M
EPS (Annual)	-$3.66
Price to Book	-30.57
Revenue Per Employee	$128,205.13
Enterprise Value/EBITDA	N/A

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VSTM News

VSTMVerastem Inc